|
WO1990004633A1
(en)
|
1988-10-21 |
1990-05-03 |
Brigham And Women's Hospital |
ACTIVATION AND GROWTH OF HUMAN TUMOR-INFILTRATING LYMPHOCYTES USING ANTIBODIES TO CD3 OR TcR
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
US5126132A
(en)
|
1989-08-21 |
1992-06-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Tumor infiltrating lymphocytes as a treatment modality for human cancer
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
EP0571525A1
(en)
|
1991-02-11 |
1993-12-01 |
OMMAYA, Ayub K. |
Spinal fluid driven artificial organ
|
|
US5222982A
(en)
|
1991-02-11 |
1993-06-29 |
Ommaya Ayub K |
Spinal fluid driven artificial organ
|
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
|
US5356802A
(en)
|
1992-04-03 |
1994-10-18 |
The Johns Hopkins University |
Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
|
|
US5487994A
(en)
|
1992-04-03 |
1996-01-30 |
The Johns Hopkins University |
Insertion and deletion mutants of FokI restriction endonuclease
|
|
US5436150A
(en)
|
1992-04-03 |
1995-07-25 |
The Johns Hopkins University |
Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
|
|
EP0705344B8
(en)
|
1993-06-24 |
2006-05-10 |
Advec Inc. |
Adenovirus vectors for gene therapy
|
|
DE69435223D1
(de)
|
1993-10-25 |
2009-09-03 |
Canji Inc |
Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7078387B1
(en)
|
1998-12-28 |
2006-07-18 |
Arch Development Corp. |
Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
GB9927328D0
(en)
|
1999-11-18 |
2000-01-12 |
Lorantis Ltd |
Immunotherapy
|
|
HK1052372A1
(zh)
|
2000-02-24 |
2003-09-11 |
Xcyte Therapies, Inc. |
细胞的同步刺激和富集
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6962810B2
(en)
|
2000-10-31 |
2005-11-08 |
University Of Notre Dame Du Lac |
Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac
|
|
WO2002088346A2
(en)
|
2001-05-01 |
2002-11-07 |
National Research Council Of Canada |
A system for inducible expression in eukaryotic cells
|
|
WO2003057171A2
(en)
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US8034334B2
(en)
|
2002-09-06 |
2011-10-11 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
|
|
US7381405B2
(en)
|
2002-10-15 |
2008-06-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer
|
|
EP2305813A3
(en)
*
|
2002-11-14 |
2012-03-28 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
AU2005250408B2
(en)
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
PT1809321E
(pt)
|
2004-10-08 |
2012-05-17 |
Us Gov Health & Human Serv |
Imunoterapia adotiva com sobrevivência aumentada de linfócitos
|
|
WO2007103901A2
(en)
|
2006-03-06 |
2007-09-13 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer
|
|
SI2019683T2
(sl)
|
2006-04-25 |
2022-10-28 |
The Regents Of The University Of California |
Dajanje rastnih faktorjev za zdravljenje motenj CŽS
|
|
US20080081064A1
(en)
|
2006-09-28 |
2008-04-03 |
Surmodics, Inc. |
Implantable Medical Device with Apertures for Delivery of Bioactive Agents
|
|
FR2911346B1
(fr)
|
2007-01-12 |
2012-12-07 |
Ct Hospitalier Universitaire De Nantes |
Procede de culture in vitro de lymphocytes t,en particulier de lymphocytes t infiltrant les tumeurs dits til
|
|
US20130331294A1
(en)
|
2007-11-09 |
2013-12-12 |
Fox Chase Cancer Center |
Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
|
|
WO2009069668A1
(ja)
|
2007-11-28 |
2009-06-04 |
National University Corporation Nagoya University |
悪性黒色腫抗原の発現上昇剤及びその用途
|
|
EP2222344A4
(en)
|
2007-11-30 |
2012-11-07 |
Baylor College Medicine |
VACCINATE COMPOSITIONS WITH DENDRITIC CELLS AND THEIR USE
|
|
WO2009097468A2
(en)
|
2008-01-29 |
2009-08-06 |
Kliman Gilbert H |
Drug delivery devices, kits and methods therefor
|
|
WO2009139921A2
(en)
|
2008-05-16 |
2009-11-19 |
Genelux Corporation |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
JPWO2010098429A1
(ja)
*
|
2009-02-27 |
2012-09-06 |
国立大学法人大阪大学 |
免疫アジュバント組成物、及びその利用
|
|
WO2010138755A1
(en)
|
2009-05-29 |
2010-12-02 |
Merck Sharp & Dohme Corp. |
Method of predicting the probability of modulation of transcript levels by rnai compounds
|
|
EP2445538A2
(en)
|
2009-06-23 |
2012-05-02 |
University Of Miami |
Aptamer-targeted sirna to inhibit nonsense mediated decay
|
|
US8383099B2
(en)
|
2009-08-28 |
2013-02-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adoptive cell therapy with young T cells
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
JP5897035B2
(ja)
|
2010-12-14 |
2016-03-30 |
ユニバーシティ オブ メリーランド,ボルチモア |
汎用の抗タグキメラ抗原受容体発現t細胞及びがんを治療する方法
|
|
US20120244133A1
(en)
|
2011-03-22 |
2012-09-27 |
The United States of America, as represented by the Secretary, Department of Health and |
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
|
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
|
WO2013059343A1
(en)
|
2011-10-17 |
2013-04-25 |
Massachusetts Institute Of Technology |
Intracellular delivery
|
|
WO2013063019A1
(en)
|
2011-10-28 |
2013-05-02 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells
|
|
JP6062371B2
(ja)
|
2011-11-18 |
2017-01-18 |
公益財団法人東京都医学総合研究所 |
神経変性疾患関連タンパク質の不溶性凝集体の製造方法
|
|
US20150017136A1
(en)
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
|
ES2728782T3
(es)
|
2012-05-25 |
2019-10-28 |
Univ California |
Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
|
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
WO2014059173A2
(en)
|
2012-10-10 |
2014-04-17 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
|
WO2014066137A1
(en)
|
2012-10-22 |
2014-05-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for enhancing cancer immunotherapy
|
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
SG10201707569YA
(en)
|
2012-12-12 |
2017-10-30 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
|
ES2749624T3
(es)
|
2013-03-14 |
2020-03-23 |
Caribou Biosciences Inc |
Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico
|
|
CA2912389C
(en)
|
2013-06-10 |
2020-01-28 |
The General Hospital Corporation D/B/A Massachusetts General Hospital |
Methods and compositions for reducing immunosupression by tumor cells
|
|
WO2014201378A1
(en)
|
2013-06-13 |
2014-12-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
|
|
KR20250012194A
(ko)
|
2013-06-17 |
2025-01-23 |
더 브로드 인스티튜트, 인코퍼레이티드 |
바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
|
|
EP3011033B1
(en)
|
2013-06-17 |
2020-02-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
WO2015039100A1
(en)
|
2013-09-16 |
2015-03-19 |
The Trustees Of The University Of Pennsylvania |
Cd137 enrichment for efficient tumor infiltrating lymphocyte selection
|
|
WO2015048577A2
(en)
|
2013-09-27 |
2015-04-02 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
|
MX2016004032A
(es)
|
2013-09-30 |
2016-06-02 |
Univ California |
Identificacion de cxcr8, un receptor de quimiocinas novedoso.
|
|
AU2014337385B2
(en)
|
2013-10-15 |
2020-04-30 |
The Scripps Research Institute |
Chimeric antigen receptor T cell switches and uses thereof
|
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
|
CN111218447B
(zh)
|
2013-11-07 |
2024-10-11 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
EP3760719A1
(en)
|
2013-11-18 |
2021-01-06 |
CRISPR Therapeutics AG |
Crispr-cas system materials and methods
|
|
WO2015089473A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
CN111206032B
(zh)
|
2013-12-12 |
2024-07-19 |
布罗德研究所有限公司 |
用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
WO2015090229A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
CA2977839C
(en)
|
2014-02-28 |
2022-07-26 |
The Royal Institution For The Advancement Of Learning / Mcgill University |
Tc-ptp inhibitors as apc activators for immunotherapy
|
|
CN122399016A
(zh)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
EP3698850A1
(en)
|
2014-03-20 |
2020-08-26 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Tumor-infiltrating lymphocytes for adoptive cell therapy
|
|
US10016421B2
(en)
|
2014-04-05 |
2018-07-10 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination
|
|
ES2980788T3
(es)
|
2014-04-10 |
2024-10-03 |
H Lee Moffitt Cancer Ct & Res |
Expansión mejorada de linfocitos infiltrantes de tumores para terapia celular adoptiva
|
|
SG11201608701QA
(en)
|
2014-04-18 |
2016-11-29 |
Editas Medicine Inc |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
JP2017524348A
(ja)
|
2014-06-10 |
2017-08-31 |
モナッシュ ユニバーシティ |
養子細胞移入のためのptpn2阻害を用いた白血球の産生方法
|
|
EP3169776B1
(en)
|
2014-07-14 |
2025-09-03 |
The Regents of The University of California |
Crispr/cas transcriptional modulation
|
|
EP3177314B1
(en)
|
2014-08-04 |
2020-10-07 |
Fred Hutchinson Cancer Research Center |
T cell immunotherapy specific for wt-1
|
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
US20170363629A1
(en)
|
2014-11-05 |
2017-12-21 |
Board Of Regents, The University Of Texas System |
Biomarkers and targets for cancer immunotherapy
|
|
EP3230452B1
(en)
|
2014-12-12 |
2025-06-11 |
The Broad Institute, Inc. |
Dead guides for crispr transcription factors
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
WO2016108926A1
(en)
|
2014-12-30 |
2016-07-07 |
The Broad Institute Inc. |
Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
|
|
US20190388469A1
(en)
|
2015-01-30 |
2019-12-26 |
The Regents Of The University Of California |
Protein delivery in primary hematopoietic cells
|
|
EP4019635A1
(en)
|
2015-03-25 |
2022-06-29 |
Editas Medicine, Inc. |
Crispr/cas-related methods, compositions and components
|
|
WO2016172359A2
(en)
|
2015-04-24 |
2016-10-27 |
The Regents Of The University Of California |
Systems for detecting, monitoring or treating diseases or conditions using engineered cells and methods for making and using them
|
|
HK1247958A1
(zh)
|
2015-05-05 |
2018-10-05 |
菲特治疗公司 |
T淋巴细胞的调节
|
|
AU2016262093B2
(en)
|
2015-05-13 |
2022-08-18 |
Seattle Children' S Hospital (Dba Seattle Children 's Research Institute) |
Enhancing endonuclease based gene editing in primary cells
|
|
KR102349677B1
(ko)
|
2015-05-28 |
2022-01-12 |
카이트 파마 인코포레이티드 |
T 세포 요법을 위해 환자를 컨디셔닝하는 방법
|
|
CA3001683C
(en)
|
2015-06-05 |
2024-06-04 |
The Regents Of The University Of California |
Methods and compositions for generating crispr/cas guide rnas
|
|
US10358467B2
(en)
|
2015-06-09 |
2019-07-23 |
The Regents Of The University Of California |
Therapeutic targets for cancer progression
|
|
WO2017004153A1
(en)
|
2015-06-29 |
2017-01-05 |
The Broad Institute Inc. |
Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
|
|
WO2017008019A1
(en)
|
2015-07-08 |
2017-01-12 |
The Johns Hopkins University |
Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy
|
|
US10829735B2
(en)
|
2015-07-21 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Methods for improving the efficacy and expansion of immune cells
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
IL292504B2
(en)
|
2015-10-20 |
2024-01-01 |
Kite Pharma Inc |
-methods of preparing t cells for t cell therapy
|
|
WO2017070042A1
(en)
|
2015-10-20 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing t cell populations using akt inhibitors
|
|
US11492670B2
(en)
|
2015-10-27 |
2022-11-08 |
The Broad Institute Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017079113A1
(en)
|
2015-11-02 |
2017-05-11 |
The United States Of America, As Represented By The Secretary, Department Of Healh And Human Services |
Methods of producing t cell populations using prolyl hydroxylase domain-containing protein inhibitors
|
|
GB201519340D0
(en)
|
2015-11-02 |
2015-12-16 |
Cambridge Entpr Ltd |
Methods of T-lymphocyte expansion
|
|
BE1023924B1
(nl)
|
2015-12-09 |
2017-09-13 |
Stairsolutions Vof |
Systeem van elementen voor het samenstellen van een trap en een trap samengesteld met elementen van zulk systeem
|
|
WO2017106657A1
(en)
|
2015-12-18 |
2017-06-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
WO2017117521A1
(en)
|
2015-12-31 |
2017-07-06 |
Berkeley Lights, Inc. |
Tumor infilitrating cells engineered to express a pro-inflammatory polypeptide
|
|
CN106967681B
(zh)
|
2016-01-13 |
2020-06-05 |
北京马力喏生物科技有限公司 |
治疗脑胶质母细胞瘤的治疗组合物
|
|
CN106967685B
(zh)
|
2016-01-13 |
2020-06-02 |
北京马力喏生物科技有限公司 |
共表达抗EGFRvIII嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
|
|
JP7189019B2
(ja)
|
2016-02-05 |
2022-12-13 |
シティ・オブ・ホープ |
中枢神経系の癌の治療のための操作されたt細胞の投与
|
|
JP2019513692A
(ja)
|
2016-02-19 |
2019-05-30 |
ジェニスフィア・エルエルシー |
核酸キャリア及び治療上の使用方法
|
|
GB201602974D0
(en)
|
2016-02-19 |
2016-04-06 |
Clube Jasper R |
Engineered cells & methods (1)
|
|
US20190241910A1
(en)
|
2016-03-11 |
2019-08-08 |
Bluebird Bio, Inc. |
Genome edited immune effector cells
|
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
|
EP3228701A1
(en)
|
2016-04-05 |
2017-10-11 |
Fundación Centro Nacional de Investigaciones Oncológicas Carlos III |
Method for preparing lymphocytes capable of infiltrating a solid tumor, lymphocytes obtainable by said method and uses thereof
|
|
ES3056995T3
(en)
|
2016-04-13 |
2026-02-25 |
Vivia Biotech Sl |
Ex vivo bite-activated t cells
|
|
WO2017191504A1
(en)
|
2016-05-03 |
2017-11-09 |
Oslo University Hospital Hf |
Validation of therapeutic t-cells
|
|
US12048717B2
(en)
|
2016-06-03 |
2024-07-30 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Use of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) agonists to improve ex vivo expansion of tumor infiltrating lymphocytes (TILS)
|
|
US9944331B2
(en)
|
2016-06-09 |
2018-04-17 |
Ford Global Technologies, Llc |
Perforated deformation region for a vehicle hood
|
|
US20200182884A1
(en)
|
2016-06-27 |
2020-06-11 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
|
JP7054397B2
(ja)
|
2016-06-27 |
2022-04-13 |
ジュノー セラピューティクス インコーポレイテッド |
Mhc-e拘束性エピトープ、結合分子ならびに関連する方法および使用
|
|
US11141434B2
(en)
|
2016-07-07 |
2021-10-12 |
Iovance Biotherapeutics, Inc. |
Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof
|
|
CN107586341A
(zh)
|
2016-07-08 |
2018-01-16 |
生命序有限公司 |
重组免疫检查点受体及免疫检查点抑制分子的共表达及应用
|
|
US10711312B2
(en)
|
2016-07-12 |
2020-07-14 |
The Regents Of The University Of California |
Methods for immunotherapy-based treatment and assessment of cancer
|
|
US11624068B2
(en)
|
2016-07-15 |
2023-04-11 |
Tufts Medical Center, Inc. |
Compositions and methods for improving immune system function
|
|
WO2018024895A1
(en)
|
2016-08-05 |
2018-02-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Immunotherapeutic uses of ex vivo generated foxp3+ regulatory t cells
|
|
MA46018A
(fr)
|
2016-08-19 |
2019-06-26 |
Bluebird Bio Inc |
Activateurs d'édition du génome
|
|
US20190262398A1
(en)
|
2016-08-23 |
2019-08-29 |
Bluebird Bio, Inc. |
Tim3 homing endonuclease variants, compositions, and methods of use
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
SG11201901757YA
(en)
|
2016-09-08 |
2019-03-28 |
Bluebird Bio Inc |
Pd-1 homing endonuclease variants, compositions, and methods of use
|
|
WO2018053463A1
(en)
|
2016-09-19 |
2018-03-22 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Artificial antigen presenting cells for genetic engineering of immune cells
|
|
EP3516045A1
(en)
|
2016-09-23 |
2019-07-31 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
|
|
US12499971B2
(en)
|
2016-09-28 |
2025-12-16 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
US12447213B2
(en)
*
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
EP3525803B1
(en)
|
2016-10-13 |
2022-12-07 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
|
US20190240257A1
(en)
|
2016-10-13 |
2019-08-08 |
The Johns Hopkins University |
Compositions and methods for identifying functional anti-tumor t cell responses
|
|
US11530395B2
(en)
|
2016-10-17 |
2022-12-20 |
2Seventy Bio, Inc. |
TGFBetaR2 endonuclease variants, compositions, and methods of use
|
|
EP4338799A3
(en)
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
CN110099998A
(zh)
|
2016-10-26 |
2019-08-06 |
艾欧凡斯生物治疗公司 |
冷冻保存的肿瘤浸润淋巴细胞的再刺激
|
|
EP3532075A4
(en)
|
2016-10-27 |
2020-07-08 |
Intima Bioscience, Inc. |
VIRAL METHODS OF MANUFACTURING GENETICALLY MODIFIED CELLS
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
US20190262400A1
(en)
|
2016-10-31 |
2019-08-29 |
H. Lee Moffitt Cancer Center And Research Institure, Inc. |
Artificial antigen presenting cells for expanding immune cells for immunotherapy
|
|
CA3042049A1
(en)
|
2016-11-03 |
2018-05-11 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and a btk inhibitor
|
|
US11865176B2
(en)
|
2016-11-08 |
2024-01-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of modulating anti-tumor immunity
|
|
US20190256603A1
(en)
|
2016-11-11 |
2019-08-22 |
Medimmune, Llc |
Anti-pd-l1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
|
|
TWI826360B
(zh)
|
2016-11-17 |
2023-12-21 |
美商艾歐凡斯生物治療公司 |
殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法
|
|
CN106658093B
(zh)
|
2016-12-27 |
2019-07-09 |
深圳市九洲电器有限公司 |
机顶盒与服务器的交互方法及系统
|
|
CN110546495B
(zh)
|
2016-12-30 |
2022-11-01 |
加利福尼亚州立大学董事会 |
用于基因组编辑t细胞的选择和传代的方法
|
|
AU2018205234B2
(en)
|
2017-01-06 |
2024-09-19 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
|
|
ES3055314T3
(en)
|
2017-01-06 |
2026-02-11 |
Iovance Biotherapeutics Inc |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
CN108342361B
(zh)
|
2017-01-25 |
2020-12-22 |
北京马力喏生物科技有限公司 |
治疗间质素阳性肿瘤的治疗组合物
|
|
CN108342363B
(zh)
|
2017-01-25 |
2021-02-12 |
北京马力喏生物科技有限公司 |
共表达抗msln嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
|
|
WO2018148378A1
(en)
|
2017-02-08 |
2018-08-16 |
Dana-Farber Cancer Institute, Inc. |
Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
|
|
EP3585398A4
(en)
|
2017-02-23 |
2020-08-19 |
Board of Regents of the University of Nebraska |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
KR20200020662A
(ko)
|
2017-04-03 |
2020-02-26 |
온콜로지, 인크. |
면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
|
|
US20200377855A1
(en)
|
2017-05-05 |
2020-12-03 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Rapid method for the culture of tumor infiltrating lymphocytes
|
|
WO2018209115A1
(en)
|
2017-05-10 |
2018-11-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
TW201919662A
(zh)
|
2017-06-05 |
2019-06-01 |
美商艾歐凡斯生物治療公司 |
對雙重難治性黑色素瘤使用腫瘤浸潤性淋巴細胞之方法
|
|
WO2019036815A1
(en)
|
2017-08-24 |
2019-02-28 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
ENHANCEMENT OF CD8 + T LYMPHOCYTES FOR ADOPTIVE CELL THERAPY BY INHIBITING PTPN1 (PTP1B) AND PTPN2 (TC-PTP))
|
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
|
US12698499B2
(en)
|
2017-10-27 |
2026-08-04 |
The Trustees Of The University Of Pennsylvania |
Identifying epigenetic and transcriptional targets to prevent and reverse T cell exhaustion
|
|
JP7557367B2
(ja)
|
2017-11-17 |
2024-09-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
細針吸引及び小生検からのtil拡大培養
|
|
CN111601882A
(zh)
|
2017-11-22 |
2020-08-28 |
拉霍拉敏感及免疫学研究所 |
工程化的免疫细胞的应用和生产
|
|
EP3724885A2
(en)
|
2017-12-15 |
2020-10-21 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
EP3737743A1
(en)
|
2018-01-08 |
2020-11-18 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
EP3765094A4
(en)
|
2018-03-15 |
2021-12-22 |
KSQ Therapeutics, Inc. |
GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY
|
|
WO2019178422A1
(en)
|
2018-03-15 |
2019-09-19 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
EA202092319A1
(ru)
|
2018-03-29 |
2021-03-04 |
Айовэнс Байотерапьютикс, Инк. |
Способы получения опухоль-инфильтрирующих лимфоцитов и применения их в иммунотерапии
|
|
EP3775213A1
(en)
|
2018-04-13 |
2021-02-17 |
Sigma Aldrich Co. LLC |
Modification of immune-related genomic loci using paired crispr nickase ribonucleoproteins
|
|
WO2019210131A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2019217753A1
(en)
|
2018-05-10 |
2019-11-14 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US20210236547A1
(en)
|
2018-06-05 |
2021-08-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Rapid production, expansion, and increased purity of car-t cells using beads with protein l
|
|
WO2019235581A1
(ja)
|
2018-06-06 |
2019-12-12 |
国立大学法人大阪大学 |
Regnase-1が関与する疾患の治療および/または予防方法
|
|
JP2021526860A
(ja)
|
2018-06-08 |
2021-10-11 |
ロックアネイビオ, インコーポレイテッド |
適応免疫をモジュレートするための組成物および方法
|
|
CN112930395A
(zh)
|
2018-06-08 |
2021-06-08 |
洛卡纳生物股份有限公司 |
靶向rna的融合蛋白组合物和使用方法
|
|
TWI888352B
(zh)
|
2018-06-21 |
2025-07-01 |
美商嘉來克生命科學有限責任公司 |
蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法
|
|
EP3830249A1
(en)
|
2018-07-31 |
2021-06-09 |
polybliocept GmbH |
Production and selection of tumor uber reactive immune cells (turics)
|
|
SG11202101787XA
(en)
|
2018-09-20 |
2021-04-29 |
Iovance Biotherapeutics Inc |
Expansion of tils from cryopreserved tumor samples
|
|
SG11202108452WA
(en)
|
2019-02-04 |
2021-09-29 |
Ksq Therapeutics Inc |
Combination gene targets for improved immunotherapy
|